Topic: IPO

PPD

PPD to go public once again

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.
Spark Therapeutics logo on labcoat

Spark Therapeutics

After launching in late 2013 with $50 million and a clutch of gene therapies out of Children’s Hospital of Philadelphia, Spark Therapeutics hit the gas. It picked up another $73 million and a Big Pharma partner en route to its upsized IPO in 2015.

Ultragenyx

In nine years, Ultragenyx grew from two employees to 700, striking partnerships, jumping into gene therapy through its acquisition of Dimension Therapeutics and getting two rare disease drugs to market.
wall street bull color

Tesaro

If Axovant was a textbook example of how not to create a company around somebody else’s castoffs, Tesaro was a model of how to do it right. The startup came to life in 2010 with a trio of cancer drug business veterans and $20 million stumped up by New Enterprise Associates.
Vivek Ramaswamy

Axovant

Axovant raised the biggest biotech IPO of 2015 but crashed and burned a few years later. Time will tell if a 2018 pivot to gene therapy will be the company's saving grace.